Arthur Allen, Gregory Piazza, Margaret Fang/LinkedIn
Sep 12, 2025, 15:44
Long-Term Apixaban Use for Provoked VTE: Focus on HI-PRO Trial by Arthur Allen, Margaret Fang and Gregory Piazza
Anticoagulation Forum shared on LinkedIn:
”Join us for our free October webinar: Emerging Evidence: Long-term oral anticoagulation following provoked VTE? A focus on the HI-PRO Trial
Tuesday, October 7, 2025 | 12:00 PM ET
Join us as expert faculty review findings from the recent HI-PRO Trial on the use of apixaban for extended treatment of provoked venous thromboembolism (VTE).
What you’ll learn:
- Key insights from trial design and results
- Clinical implications for real-world practice
- Patient selection considerations for extended therapy
Faculty:
Arthur Allen, PharmD, CACP – Salt Lake City Va Health Care System
Margaret Fang, MD, MPH – University of California, San Francisco
Gregory Piazza, MD, MS – Brigham and Women’s Hospital”
Register here.
Stay informed on all webinars and seminars in the field of thrombosis with Hemostasis Today.
-
Aug 11, 2026, 06:48Rishdha Roshad: What Happens to the Brain During Cardiopulmonary Bypass?
-
Aug 11, 2026, 05:53Isaac Okello: Strengthening Sickle Cell Advocacy in Uganda
-
Aug 11, 2026, 05:38Rami Unterman: A Simple New Biomarker for Fibrotic ILDs
-
Aug 11, 2026, 04:10Haroun Gajraj: CLaCS vs Sclerotherapy – What Does the Evidence Show
-
Aug 11, 2026, 02:54Tareq Abadl: The Ultimate Guide to Clinically Significant Antibodies
-
Aug 10, 2026, 17:35Chokri Ben Lamine: Balancing Holistic Care and Precision in Hematology
-
Aug 10, 2026, 17:14Anna Stanizzi: Patient Blood Management as a New Model of Personalized Care
-
Aug 10, 2026, 17:12Odong Christopher: New Research on Ischemic Stroke Prediction in Uganda
-
Aug 10, 2026, 16:58Jeff Szer AM: Advancing the Management of Paroxysmal Nocturnal Hemoglobinuria